We are live on ! Find out more
IART icon

Integra LifeSciences

264 hedge funds and large institutions have $5.09B invested in Integra LifeSciences in 2021 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 95 increasing their positions, 77 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 29

23% more repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 77

3% more funds holding

Funds holding: 257264 (+7)

0.95% more ownership

Funds ownership: 87.5%88.46% (+0.95%)

0% more capital invested

Capital invested by funds: $5.09B → $5.09B (+$4.06M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
264
Holders Change
+7
Holders Change %
+2.72%
% of All Funds
4.6%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
38
Increased
95
Reduced
77
Closed
29
Calls
$1.71M
Puts
Net Calls
+$1.71M
Net Calls Change
+$1.23M

IART Hedge Fund Activity: Q2 2021 in Review

264 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2021, worth a combined $5.09B — up 0.08% from $5.09B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new IART positions and 29 closed out — a net gain of 9 holders — while 95 added to existing stakes and 77 trimmed.

The largest buyer was Eaton Vance Management, adding an estimated $14.8M. The largest seller was Invesco, cutting an estimated $17.9M.

  • 264 institutional investors held Integra LifeSciences (IART) as of Q2 2021, up from 257 in Q1 2021.
  • Funds reported $5.09B of Integra LifeSciences stock for Q2 2021, up 0.08% quarter-over-quarter.
  • 38 funds opened new Integra LifeSciences positions in Q2 2021 and 29 closed out, a net change of +9 holders.
  • The largest Integra LifeSciences buyer in Q2 2021 was Eaton Vance Management, an estimated $14.8M added.
  • The largest Integra LifeSciences seller in Q2 2021 was Invesco, an estimated $17.9M sold.

Based on aggregated 13F filings for Q2 2021.